For patients with atrial fibrillation, anticoagulant therapy is essential to reduce the risk of ischemic stroke that is associated with this arrhythmia. Historically, warfarin has been the preferred treatment for patients at moderate to high risk despite many potential limitations. With the development of newer oral anticoagulants, clinicians now have 3 additional options: dabigatran, rivaroxaban, and apixaban. Although these agents clearly offer some advantages over warfarin, they may not be appropriate for all patients. This article will discuss factors that should be considered when selecting among these various anticoagulants.
WolfPAAbbottRDKannelWB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke1991;22(8):983–988.
2.
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published correction in Arch Intern Med. 1994;154(19):2254]. Arch Intern Med.1994;154(13):1449–1457.
3.
YouJJSingerDEHowardPA. Antithrombotic therapy for atrial fibrillation antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(Suppl):e531S-575S.
4.
RajiMALoweryMLinYL. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother.2013;47:35–42.
5.
ConnollySJEzekowitzMDYusufS. Dabigatran versus warfarin in patients with atrial fibrillation [erratum N Engl J Med. 2010;363:1877]. N Engl J Med.2009;361:1139–1151.
6.
ConnollySJEzekowitzMDYusufS. Newly identified events in the RE-LY trial [letter]. N Engl J Med.2010;363:1875–1876.
7.
FDA investigating serious bleeding events with dabigatran. Medscape. Published December 7, 2011. http://www.medscape.com/viewarticle/754953. Accessed February 19, 2013.
PatelMRMahaffeyKWGargJ. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med.2011;365:883–891.
10.
GrangerCBAlexanderJHMcMurrayJJ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med.2011;365(11):981–992.
11.
Van de WerfFBrueckmanMConnollySJ. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J.2012;163:931–937.e1.
12.
FDA drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. December 19, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm. Accessed February 20, 2013.
UchinoKHernandezAV. Dabigatran association with higher risk of acute coronary events. Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med.2012;172:397–402.
17.
LlauJVFerrandisR.New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol.2009;22:661–666.
18.
StangierJ.Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet.2008;47:285–295.
19.
KreutzR.Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26(1):27–32.
20.
FrostCWangJNepalS. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor [abstract 139]. J Clin Pharmacol. 2009;49:1123.
21.
VakkalagaddaBFrostCWangJ. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract 143]. J Clin Pharmacol. 2009;49:1124.
22.
BaglinTHillarpATripodiA. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis [published online ahead of print January 24, 2013]. J Thromb Haemost. doi: 10.111/jth.12149.
23.
van RynJStangierJHaertterS. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost.2010;103:1116–1127.
24.
EerenbergESKamphuisenPWSijpkensMK. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation.2011;124:1573–1579.
25.
SchirmerSHBaumhäkelMHans-Ruprecht NeubergerHR. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol.2010;56:2067–2076.
26.
PatelMRHellkampASLokhnyginaY. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation. Analysis from the ROCKET AF trial. J Am Coll Cardiol.2013;61:651–658.
